Microvessel density and VEGF/VEGF receptor status and their role in sarcomas of the pulmonary artery

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 309-318

  Gaumann, Andreas K A ^a,b   Schermutzki, Gero ^b   Mentzel, Thomas ^c   Kirkpatrick, C James ^b   Kriegsmann, Joerg B ^d   Konerding, Moritz A ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Dermatopathologische Gemeinschaftspraxis   (Germany)

^d Center of Histopathology Cytology and Molecular Pathology Trier   (Germany)

Author keywords

Angiogenesis; Morphometry; Sarcoma; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

CARBOPLATIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; MICROVASCULATURE; MORPHOMETRICS; MULTIPLE CYCLE TREATMENT; NECROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY VASCULAR DISEASE; RECEPTOR UPREGULATION; SARCOMA; SOFT TISSUE SARCOMA; TUMOR CELL; TUMOR DIFFERENTIATION;

ADULT; AGED; CAPILLARIES; FACTOR VIII; FEMALE; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY ARTERY; SARCOMA; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR NEOPLASMS;

EID: 38749119719     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mingoli A, Cavallaro A, Feldhaus RJ, et al: Inferior vena cava leiomyosarcoma: establishment of an international registry. Eur J Vasc Surg 8: 380-381, 1994.
2. McGlennen RC, Manivel JC, Stanley SJ, et al: Pulmonary artery trunk sarcoma: a clinicopathologic, ultrastructural, and immunohistochemical study of four cases. Mod Pathol 2: 486-494, 1989.
3. Burke AP and Virmani R: Sarcomas of the great vessels. A clinicopathologic study. Cancer 71: 1761-1773, 1993.
4. Hottenrott G, Mentzel T, Peters A, Schroder A and Katenkamp D: Intravascular ('intimal') epithelioid angiosarcoma: clinicopathological and immunohistochemical analysis of three cases. Virchows Arch 435: 473-478, 1999.
5. Mayer E, Kriegsmann J, Gaumann A, et al: Surgical treatment of pulmonary artery sarcoma. J Thorac Cardiovasc Surg 121: 77-82, 2001.
6. Gaumann A, Tews DS, Mentzel T, et al: Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch 442: 529-537, 2003.
7. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
8. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
9. Issbrucker K, Marti HH, Hippenstiel S, et al: p38 MAP kinase - a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J 17: 262-264, 2003.
10. Matsumoto T and Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 2001: RE21, 2001.
11. Paradis V, Lagha NB, Zeimoura L, et al: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 436:351-356, 2000.
12. Cheng N, Brantley DM, Liu H, et al: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11, 2002.
13. Heidenreich R, Machein M, Nicolaus A, et al: Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int J Cancer 111: 348-357, 2004.
14. Weidner N: Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 31: 403-405, 2000.
15. Li C, Gardy R, Seon BK, et al: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88: 1424-1431, 2003.
16. Straume O and Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159: 223-235, 2001.
17. Hazar B, Paydas S, Zorludemir S, Sahin B and Tuncer I: Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 44: 2089-2093, 2003.
18. Tomisaki S, Ohno S, Ichiyoshi Y, et al: Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 77: 1722-1728, 1996.
19. Tomlinson J, Barsky SH, Nelson S, et al: Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 5: 3516-3522, 1999.
20. Kawauchi S, Fukuda T and Tsuneyoshi M: Angiogenesis does not correlate with prognosis or expression of vascular endo-thelial growth factor in synovial sarcomas. Oncol Rep 6: 959-964, 1999.
21. Theegarten D, Zorn M and Philippou S: Proliferative activity, p53 accumulation and neoangiogenesis in pulmonary carcinosarcomas and pulmonary blastomas. Gen Diagn Pathol 143: 265-270, 1998.
22. Mentzel T, Brown LF, Dvorak HF, et al: The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 438: 13-22, 2001.
23. Konerding MA, Fait E and Gaumann A: 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84: 1354-1362, 2001.
24. Vermeulen PB, Gasparini G, Fox SB, et al: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38: 1564-1579, 2002.
25. Gasparini G, Fanelli M, Boracchi P, et al: Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen. Clin Exp Metastasis 18: 15-20, 2000.
26. Hlatky L, Hahnfeldt P and Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893, 2002.
27. Chou CY, Huang SC, Tsai YC, Hsu KF and Huang KE: Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol Oncol 65:225-231, 1997.
28. Emoto M, Iwasaki H, Ishiguro M, et al: Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 30: 1232-1241, 1999.
29. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961, 2002.
30. Zagzag D, Amirnovin R, Greco MA, et al: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80: 837-849, 2000.
31. Yancopoulos GD, Davis S, Gale NW, et al: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
32. Gerber HP, Condorelli F, Park J and Ferrara N: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not F1k-1/KDR, is up-regulated by hypoxia. J Biol Chem 272: 23659-23667, 1997.
33. Nomura M, Yamagishi S, Harada S, et al: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270: 28316-28324, 1995.
34. Kremer C, Breier G, Risau W and Plate KH: Up-regulation of flk-1/ vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 57: 3852-3859, 1997.
35. Clauss M, Weich H, Breier G, et al: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271: 17629-17634, 1996.
36. Dias S, Hattori K, Zhu Z, et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106: 511-521,2000.
37. Dias S, Hattori K, Heissig B, et al: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 98: 10857-10862, 2001.